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Abstract
Background: The heat shock protein 90 (Hsp90) is required for the stability of many signalling kinases. As a target
for cancer therapy it allows the simultaneous inhibition of several signalling pathways. However, its inhibition in
healthy cells could also lead to severe side effects. This is the first comprehensive analysis of the response to
Hsp90 inhibition at the kinome level.
Methods: We quantitatively profiled the effects of Hsp90 inhibition by geldanamycin on the kinome of one primary
(Hs68) and three tumour cell lines (SW480, U2OS, A549) by affinity proteomics based on immobilized broad spectrum
kinase inhibitors ("kinobeads”). To identify affected pathways we used the KEGG (Kyoto Encyclopedia of Genes and
Genomes) pathway classification. We combined Hsp90 and proteasome inhibition to identify Hsp90 substrates in Hs68
and SW480 cells. The mutational status of kinases from the used cell lines was determined using next-generation
sequencing. A mutation of Hsp90 candidate client RIPK2 was mapped onto its structure.
Results: We measured relative abundances of > 140 protein kinases from the four cell lines in response to
geldanamycin treatment and identified many new potential Hsp90 substrates. These kinases represent diverse
families and cellular functions, with a strong representation of pathways involved in tumour progression like the
BMP, MAPK and TGF-beta signalling cascades. Co-treatment with the proteasome inhibitor MG132 enabled us to
classify 64 kinases as true Hsp90 clients. Finally, mutations in 7 kinases correlate with an altered response to Hsp90
inhibition. Structural modelling of the candidate client RIPK2 suggests an impact of the mutation on a proposed
Hsp90 binding domain.
Conclusions: We propose a high confidence list of Hsp90 kinase clients, which provides new opportunities for
targeted and combinatorial cancer treatment and diagnostic applications.
Background
H s p 9 0i sp a r to ft h em o l e c u l a rc h a p e r o n e sf a m i l y
responsible for ATP-dependent folding and activation of
proteins. Unlike other chaperones, Hsp90 is in most
cases not involved in the de novo folding of proteins but
stabilizes folded conformations and regulates protein
degradation [1]. Another important difference is the
selectivity of Hsp90 for its substrates, which therefore
are called clients. Most of these client proteins are
involved in signal transduction, including kinases,
nuclear hormone receptors and transcription factors [2].
A potential role for Hsp90 in tumourigenesis has been
suggested. Many types of tumours show an elevated
level of Hsp90 correlated with a poor prognosis (e.g.
[3,4]). This elevation is attributed to increased cellular
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and increased dependency of mutated proteins on
Hsp90 [1]. Known oncogenic Hsp90 clients include
kinases such as SRC, CDK4, BRAF and ErbB2. Currently
14 Hsp90 inhibitors are evaluated in different stages of
clinical development [5,6].T h e s ec o m p o u n d sb i n dt o
the N-terminal ATPase-pocket, thereby disturb the cha-
perone cycle and lead to the depletion of Hsp90 sub-
strates by proteasomal degradation [5]. Tumours are
more susceptible to Hsp90 inhibitors than normal tis-
sues because all Hsp90 protein is thought to become
associated with its substrates in large chaperone com-
plexes with high affinity for inhibitors like geldanamycin
or 17-AAG [7]. To optimize future chemotherapeutic
treatment and outcome, and to minimize side effects, it
is essential to understand the molecular consequences
of inhibiting Hsp90-dependent pathways and to define
Hsp90-client protein interactions.
In the past, mass spectrometry (MS)-based proteomic
approaches, yeast-two-hybrid screens and a genomic
screen of yeast deletion strains were used to elucidate
substrates and co-chaperones of Hsp90 and cellular
pathways it acts upon [8-15].
This study represents the first comprehensive mapping
of the Hsp90 client kinome. We employed a kinase-
directed chemoproteomics approach [16] to assess the
protein levels of kinases after Hsp90 inhibition by gelda-
namycin in frequently used cell lines of three different
tumour origins and one primary cell line in order to
identify novel clients of Hsp90 and define cancer-rele-
vant differences between non-transformed cells and can-
cer cells.
Methods
Cell culture
Hs68, U2OS, SW480 and A549 cells were obtained from
American Type Culture Collection (ATCC) and grown
in DMEM supplemented with 10% FCS and 1% L-Gluta-
mine at 37°C and 5% CO2. Glucose content was 1 g/l
for U2OS and 4 g/l for all other cell lines. Cells were
treated with 1.78 μM( 1μg/ml) geldanamycin (Biomol)
solubilised in DMSO (Merck) for 12 or 24 h or with
DMSO alone (control) for 24 h. Experiments were per-
formed twice, in an independent manner. Cells were
lysed in 50 mM Tris pH 7.4, 5% glycerol, 1.5 mM
MgCl2,1 5 0m MN a C l ,1m MN a 3VO4,2 5m MN a F ,
0.4% NP-40 and 1 mM DTT. For combined inhibition
of the proteasome and Hsp90 20 μM of MG132 (Sigma)
o rt h es a m ev o l u m eo fD M S Oa sac o n t r o lw e r ea d d e d
for the last 6 h of geldanamycin treatment.
Mass spectrometry
Lysates were used for kinobea d sa n a l y s i sa sp r e v i o u s l y
described [16]. Experimental design, mass spectrometry
and statistical analyses are detailed in the Additional file
1. Only kinases with a P-value < 0.05 between duplicates
were considered for further analysis.
Next generation sequencing
Agilent Sure Select Enrichment of exonic regions,
SOLiD next generation sequencing and bioinformatic
workflow are detailed in Additional file 1.
Structural analysis
Structural information on ErbB1/EGFR (PDB 1m14) was
obtained from the Protein Data Bank (PDB) and the
structure of RIPK2 is from the SWISS-MODEL Reposi-
tory [17], based on template 2eva from PDB. Visualiza-
tions were done with PyMol.
Results
Targeted proteomics quantifies relative changes of kinase
levels after Hsp90 inhibition
Hsp90 is required for the function and stability of a
multitude of oncogenes. To better understand the com-
plexity of Hsp90-dependent cellular signalling in normal
and in cancer cells we analyzed the effect of the Hsp90
inhibitor geldanamycin on kinase abundance at 12 and
24 h. Kinases, which constitute the largest group of
Hsp90 clients, are often difficult to quantify in whole
cell protein extracts by mass spectrometry (MS) due to
their low abundance, which hampers their quantitative
detection in large numbers. In order to circumvent this
problem, we enriched kinases using a sepharose matrix
with immobilized broad spectrum kinase inhibitors
(kinobeads) prior to quantitative MS analysis [16,18].
This technology allows the precise differential quantifi-
cation of kinase expression levels. Experiments were car-
ried out as independent biological replicates in order to
ensure reproducibility and reliability.
As a starting point we used the Hs68 primary foreskin
fibroblast cell line to analyze the effects of geldanamycin
on kinase levels in non-transformed cells. These results
were compared to the response to the same treatment
on cancer cell lines of different origin: osteosarcoma
(U2OS), colon adenocarcinoma (SW480) and lung ade-
nocarcinoma (A549). Upon kinobeads enrichment we
quantified a total of 144 kinases from those four cell
lines using a combination of isobaric mass tags and tar-
geted MS technology [19] (Figure 1a and Additional file
2: Table S1). Among these, 46 have been described
before as likely Hsp90 client proteins (Additional file 3:
Table S2). We confirmed a significant decrease in the
level of all of these kinases in at least one cell line after
24 h of geldanamycin treatment. More surprisingly, 26
of the 29 known Hsp90 client kinases that we also
quantified in the reference Hs68 cell line showed signifi-
cantly reduced levels after 24 h of treatment, including
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kinase name confirmed
Hs68 SW480 U2OS A549 interaction inhibitor effect client
ACTR2 0.27 0.23 0.81 none none -
ALK2 0.44 0.25 0.37 0.37 none none yes
ALK4 0.24 0.49 none none yes
ARG 0.39 0.39 0.32 0.44 none none yes
BMPR1A 0.21 0.15 none none -
BMPR2 0.65 0.69 0.56 none none -
BRK 0.20 0.33 none none yes
CaMK1d 0.68 0.63 none none -
CaMK2b 0.63 0.62 none none -
CDK10 0.64 0.54 none none -
CDK5 0.71 0.56 0.48 0.47 - none yes
CK1a 0.47 0.32 0.44 0.60 +n o n e-
DDR1 0.30 0.32 0.43 none none yes
DDR2 0.27 0.29 none none no
DNAPK 0.63 0.64 0.78 0.50 +- y e s
EphA4 0.27 0.29 0.31 none none -
EphB2 0.73 0.82 0.65 0.53 none none -
EphB3 0.64 0.58 0.53 none none -
EphB4 0.43 0.41 0.45 0.67 none none no
EphB6 0.25 0.29 none none no
FES 0.49 +n o n e-
FGFR1 0.47 0.49 0.44 0.57 none none -
IKKe 0.75 0.41 0.51 0.52 +n o n e n o
KHS1 0.73 0.43 0.45 0.52 none none yes
KHS2 0.54 0.47 0.51 none none -
MAP2K5/MEK5 0.52 0.51 none - -
MAP3K1/MEKK1 0.34 0.52 +--
MAP3K2/MEKK2 0.79 0.29 0.44 0.38 none none no
MAP3K4/MEKK4 0.85 0.63 0.63 0.66 none none -
MELK 0.64 0.44 none none -
MSK2 0.64 0.46 none none yes
MYT1 0.50 0.53 0.41 0.58 none none yes
NEK9 0.75 0.91 0.51 0.45 none none yes
NLK 0.35 0.41 none none yes
PKN1 0.51 0.45 0.57 none none yes
QIK 1.35 0.37 0.48 none none yes
QSK 0.63 0.63 none none -
RIPK2 0.58 0.24 0.39 0.36 none none yes
SIK 0.69 0.60 none none no
TAO1 0.72 0.60 0.61 none none -
TAO2 0.52 0.42 0.57 0.56 none none -
TAO3 0.52 0.49 0.65 none none -
TNK1 0.28 0.46 none none yes
ZAK 0.68 0.41 0.35 0.49 +n o n e-
FC vs DMSO known connections to Hsp90
Figure 1 Changes in kinase abundance upon geldanamycin treatment. Relative quantification of kinases identified from Hs68, SW480, U2OS
and A549 cells treated with geldanamycin for 24 h following enrichment on Kinobeads (from two independent experiments). Fold change refers
to the ratio between geldanamycin-treated and DMSO-treated cells. a) Heat map representation of the effect of Hsp90 inhibition on the level of
the 144 quantified kinases (log2 scale). Kinases are grouped in classes according to structural similarity of their catalytic domain. b) List of
putative new Hsp90 kinase clients identified. Kinases were selected as client candidates if their log2 ratio (fold change treated versus untreated
cells) is greater than-0.5 in Hs68 cells or in at least two cancer cell lines. The results are compared to literature data for evidence of previous
associations (Additional file 5).
Haupt et al. BMC Cancer 2012, 12:38
http://www.biomedcentral.com/1471-2407/12/38
Page 3 of 12well known cancer-relevant proteins like EGFR, Met and
PDGFRa/b. This was unexpected since healthy cells are
thought to be poorly responsive to geldanamycin treat-
ment. Alternatively, Hs68 cells may not be a perfect
substitute for a normal, healthy cell, therefore minimiz-
ing the difference to cancer tumoural cells. Overall, 69%
of all kinases quantified from Hs68 cells display signifi-
cantly reduced levels after 24 h, a figure substantially
lower than the 80 to 88% observed in the three cancer
cell lines. Increased kinase abundance upon geldanamy-
cin treatment was detected for nine kinases from Hs68
cells including JNK2, p38a, RSK2, ERK2 and AMPKA1,
but only Aurora A kinase exhibited an increase in excess
of 50% (+155%). Only Aurora A kinase is more abun-
dant in kinobeads precipitates from the three cancer cell
lines (from +85% in U2OS to +160% in A549 cells). The
expression level of Aurora A is strongly regulated during
cell cycle with a peak in mitosis. It is possible that the
observed increase is due to an arrest of the cells at the
G2/M checkpoint or in mitosis. Changes in relative
kinase abundances were confirmed by immunoblotting
(Additional file 4: Figure S1). As an internal control of
geldanamycin treatment, components of the Hsp90 cha-
perone machinery are, as expected, strongly up-regu-
lated when quantified directly from lysate (Additional
file 3: Table S3) [20].
Identification of potential new Hsp90 clients
We sought to identify potential new Hsp90 client pro-
teins from our dataset to expand the knowledge about
targets of Hsp90-based therapy. As classification criteria
for new Hsp90 clients we set a protein level decrease
after 24 h geldanamycin treatment of at least 30% (P-
value < 0.01%) when compared to untreated cells, in
either Hs68 or in at least two cancer cell lines (high
confidence) or in only one cancer cell line. We retrieved
44 high confidence candidate clients (Figure 1b and
Additional file 3: Table S2) with an average protein level
reduction of 48%. We find the same extend of decrease
for several known clients, which suggests a high prob-
ability that these are true clients. Amongst the high con-
fidence candidates we identified five Ephrin receptors,
MAP2K5, three MAP3Ks, all three Tao kinases, CK1a,
CDK5, PLK4, NEK9, MYT1, DDR1 and DDR2, which
points to a broader involvement of Hsp90 in signalling
processes than previously thought. A few of these
kinases (e.g. MAP3K1, CK1a, FES, IKKe) have already
been shown to interact with Hsp90, but we found no
evidence of Hsp90 inhibition effects on these kinases
described in the literature (Figure 1b). The decrease of
the levels of BMP receptors (BMPR1a, BMPR2, ALK2,
and ACTR2) implies the Hsp90 machinery in BMP sig-
nalling. The BMP pathway has been proposed to have a
role in cancer progression similar to that of TGF-beta
signalling [21,22].
Changes in kinase levels upon Hsp90 inhibition are rapid
and dynamic
To gain insight into the temporal dynamics of kinase
level changes we investigated geldanamycin effects after
12 h and 24 h treatment. We classified kinases into four
groups according to their pattern of protein level change
( F i g u r e2 aa n dA d d i t i o n a lf i l e3 :T a b l eS 4 ) .T h ef i r s t
class includes kinases that have unchanged levels follow-
ing drug treatment. The second group displays
decreased levels at 12 h, but no further decrease at 24 h
(Figure 2a, “fast” decrease). The third group shows
reduced levels at 12 h and further decrease at 24 h (Fig-
ure 2a, “slow” decrease). The last class regroups kinases
presenting other patterns. In Hs68 cells we observe that
63% of all kinases show “fast” decrease kinetics, 1% a
“slow” decrease and 24% appear unaffected. Amongst
cancer cell lines, SW480 cells showed the largest simi-
larity to Hs68 with more kinases with either “fast” (68%)
or “slow” (8%) decrease kinetics, while less are unaf-
fected (19%). U2OS cells differ prominently from Hs68
cells by an increased number of kinases with “slow”
decrease kinetics (28%) along with a reduction of “fast”
decrease kinetics kinases of the same magnitude. A549
cells display an intermediary pattern between those of
Hs68 and SW480 cells. Therefore, some differences can
be observed between the reference cell line and tumour
cells, but no striking discrepancy in the kinetics of
kinase amount reduction.
Cellular pathways are differentially impacted by Hsp90
inhibition
Knowledge about the client response to Hsp90 inhibi-
tion is often derived from cancer cells. However, this
might not reflect the behaviour of Hsp90-client interac-
tions in normal, healthy cells. The distinction is of parti-
cular interest to predict possible side effects in therapy.
Recently, it has been shown that Hsp90 inhibition indir-
ectly promotes the growth of metastasing prostate carci-
noma cells in the bone by primarily affecting the normal
tumour-surrounding tissue [23].
Even though expression of many kinases is decreased
in the primary cell line Hs68 following geldanamycin
treatment, the level of some kinases appears unaffected
by the treatment, or is slightly increased in Hs68 despite
a strong decrease in cancer cells (e.g. QIK, BIKE, RSK2).
It is possible that cancer cells show more generally a
stronger decrease of key kinases than that observed in
Hs68 cells after treatment. Hence, we compared protein
level changes following geldanamycin treatment (24 h)
of the 75 kinases quantified in Hs68 with those of
Haupt et al. BMC Cancer 2012, 12:38
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Figure 2 Differential effects of Hsp90 inhibition in primary cells and in cancer cells lines. a) Quantitative mapping of kinase populations in
Hs68, U2OS, SW480 and A549 cells after geldanamycin treatment at two time intervals. Protein level changes over time at 12 h and 24 h were
analyzed and kinases with similar behaviour were grouped as defined in the main text. Pie charts show for each cell line the relative proportion
of respective groups compared to all quantified kinases. Log2 ratio fc (treated versus untreated cells) of -0.4,-0.8 and 0.4 were used as thresholds.
b) Many kinases are strongly decreased in cancer cells when compared to non-transformed Hs68 cells. Kinase log2 ratio fc (24 h treated versus
untreated cells) of cancer cells are compared to those of Hs68 cells. Differences of more than -0.5 were considered as differential and the graph
shows kinases with an effect in at least two cell lines. c) Kinases from heat map data from Figure 1A are grouped according to KEGG (Kyoto
Encyclopedia of Genes and Genomes) pathway classification. Candidate Hsp90 clients are in bold. Delta average of the log2 ratio (24 h treated
versus untreated) and the respective percentage difference between each cancer cell line and Hs68 is displayed. fc - fold change.
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Page 5 of 12cancer cells. We assumed a strong differential response
to geldanamycin treatment when the difference in the
log2 of the fold change (treated versus untreated)
between a cancer cell line and Hs68 was greater than
-0.5 (corresponding to a difference of about 30%). This
threshold was met in at least one cancer cell line by 39
(52%) kinases (Additional file 3: Table S5) and by 23
kinases in at least two cell lines, including CDK5, CSK,
LYN, RSK2 and YES (Figure 2b). Indeed, this points
towards an increased responsiveness of cancer cell lines.
We suggest that this reflects their stronger dependency
on Hsp90, which has been connected to a higher affinity
to inhibitors [7].
Looking on a pathway level using the KEGG classifica-
tion we found the MAPK signalling pathway as the most
prominent pathway in our dataset with a total of 33
kinases including 14 candidate clients (Figure 2c)[24].
For TGF-beta signalling, 9 kinases were identified, with
five selected as putative new Hsp90 clients (ACTR2,
ALK2, ALK4, BMPR1A and BMPR2). We also identified
8 cell cycle related proteins. To assess the overall impact
of geldanamycin treatment on these pathways, we com-
pared the average protein level change (treated versus
untreated) for the non-transformed Hs68 cell line with
that of each cancer cell line (only kinases quantified in
the two cell lines being compared have been consid-
ered). In all three cases, kinases of the MAPK pathway
were significantly less affected in the Hs68 cell line. The
reduction of average kinase abundance for cancer cell
lines as compared to Hs68 was 25% (SW480), 21%
(U2OS) and 23% (A549). Similar results were obtained
for the TGF-beta pathway with cancer cell lines exhibit-
ing more pronounced effects (between 14 and 27%).
S t r i k i n g l y ,h o w e v e r ,w h e nk inases involved in cell cycle
regulation were considered, the difference between Hs68
and the three other cell lines was small (Figure 2c). This
indicates that pathways may be differentially affected by
Hsp90 inhibition in primary and cancer cells.
Kinase dependency on Hsp90 is drastically increased in
cancer cells
Geldanamycin treatment impacts the protein levels of a
considerable fraction of the proteome either in a direct,
Hsp90-dependent manner (for client proteins) or by
indirect mechanisms [25]. Therefore, we determined to
what extent the observed downregulation effects were a
consequence of Hsp90-mediated proteasomal degrada-
tion by combining geldanamycin treatment with protea-
some inhibition by MG132 during the last 6 hours. We
choose to compare Hs68 and SW480 cells to detect
potential differences between a primary and a cancer
cell line. 53 and 91 kinases were identified and quanti-
fied from Hs68 and SW480 cells, respectively (Addi-
tional file 6: Table S6). After geldanamycin treatment,
40 kinases (75%) from Hs68 cells and 80 kinases (88%)
from SW480 cells were recovered at significantly lower
levels as compared to untreated cells (Additional file 6:
Table S6). The amplitude of the decrease of kinase
levels is larger than for the initial experiment and much
bigger from SW480 than from Hs68 lysates: 50 kinases
with levels reduced more than 75% in SW480 versus 10
in Hs68 (respectively 63% and 25% of all decreased
kinases), likely due to a more efficient geldanamycin
treatment (see Figure 2b). The list of kinases exhibiting
the most pronounced downregulation closely matches
the results of the first set of experiments. Additionally
we identified kinases strongly decreased by geldanamy-
cin that were not quantified in the previous experiment:
STK33 and CamK2g i nS W 4 8 0a n dA C T R 2a n dE p h 4 a
in Hs68 cells.
The addition of the proteasome inhibitor MG132 in
the last 6 h of geldanamycin treatment was expected to
stop degradation of client kinases and therefore increase
their levels [5]. Non-client kinases which may exhibit
downregulation downstream of client kinases or are
affected via another mechanism following geldanamycin
addition should not show this trend. In SW480 cells, 64
(86%) of the kinases affected by geldanamycin treatment
showed increased levels following addition of MG132
(Figure 3). Some kinases, which displayed a reduction of
more than 75%, again reached levels similar to those
detected in untreated cells, e.g. MST1, MST2, CamK2g
or PRKCa. Strikingly, only three kinases downregulated
after geldanamycin treatment from Hs68 cells, CDK5,
CK2a2 and CK1e, showed increased levels following
MG132 addition (Figure 3). This result suggests that the
observed decrease of kinase levels in Hs68 is not due to
strong Hsp90-dependent proteasomal protein
processing.
In this dataset we quantified 28 known client kinases
of which 25 showed the expected upregulation of their
protein levels after MG132 addition, validating our
approach to identify Hsp90 kinase clients. Among the
proposed 44 clients (Figure 1b) 16 out of the 23 new cli-
ents quantified in the MG132 experiment were found
significantly increased after combined geldanamycin and
proteasome inhibitor treatments (fold change geldana-
mycin + MG132 vs. geldanamycin > 1.2 and p-value <
0.01), supporting the notion that these are true Hsp90
clients. Additionally we find 18 kinases among our good
confidence candidate group confirmed by this method
(Additional file 3: Table S2). In total we identified 64
kinases from Hs68 and SW480 cells which can be classi-
fied as true Hsp90 clients, because their degradation by
geldanamycin was significantly rescued by MG132 treat-
ment. Notably, kinases from SW480 cells were more
dependent on Hsp90 than their counterparts in Hs68
cells.
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Page 6 of 12Structural analysis of kinase mutations and differential
inhibition effects
Mutations can modify the dependency of oncogene pro-
teins for Hsp90 chaperoning. For example, normal c-Src
requires Hsp90 only at an early stage for maturation.
Constitutive kinase activity of the unstable truncated
mutant requires a stronger association, rendering it
more susceptible to Hsp90 inhibition [1]. In contrast,
stabilising mutations can render PLK1 more stable, less
dependent of Hsp90 activity and hence less susceptible
to degradation upon Hsp90 inhibition [26].
We examined by next generation sequencing the cod-
ing regions of all 144 kinase genes that we had charac-
terised by targeted proteomics in Hs68, SW480, U2OS
and A549 cells. Among these, 73 had at least one mis-
sense mutation (Additional file 7: Table S7). We filtered
out mutations that were not present in dbSNP and that
were not predicted to affect protein function by using
Polyphen and MutationTaster (Additional file 1). After
filtering we obtained a set of 24 kinases (Figure 4a).
In order to test if there is a correlation between the pro-
tein level after geldanamycin treatment and the presence
of a mutation, we compared the protein level changes in
wt and mutated cell lines (Figure 4a). Indeed, we find
the strongest differential response to geldanamycin for
seven kinases in the cell line carrying the mutation
(Cdk2, Ilk, MAP3K1, MET, PAK4, PDGFRb, RIPK2).
Among these, five kinases show an elevated protein
level after geldanamycin treatment compared to a cell
line lacking the mutation. These are potentially exam-
ples of clients that have, at least partially, lost their
dependency on Hsp90 and evade Hsp90 inhibition
effects, which could impair effectiveness of cancer treat-
ment. We also identify kinases for which the same
mutation leads to a stronger decrease after geldanamy-
cin treatment in only one of two different cell lines (e.g.
kinase kinase kinase
name Hs68 SW480 name Hs68 SW480 name Hs68 SW480
AAK1 3.15 EphB4 1.14 NEK9 7.18
ABL 1.53 EphB6 1.28 NLK 4.88
ACK 0.74 1.53 Erk2 6.24 p38a 1.21
ALK2 1.17 2.26 FAK 4.16 p38b 0.85
ALK4 1.90 FER 0.71 PAK4 0.90 1.78
AMPKa1 0.72 3.16 FES 0.77 PDK1 6.81
AMPKa2 1.55 FYN 1.28 PIP5K2C 1.45
ARG 1.72 GAK 2.67 PKCa 11.62
AurA 0.88 GSK3A 4.96 PKCd 9.24
BIKE 2.30 GSK3B 1.42 PKG1 0.91
BRK 2.32 IKKe 1.81 PKN1 5.78
CaMK2g 0.59 12.21 ILK 1.60 PKN2 0.47 1.72
CaMKK1 0.77 1.52 JAK1 1.65 PLK4 5.17
CaMKK2 0.76 1.35 JNK1 4.30 PYK2 3.16
CDK2 0.24 1.45 JNK2 1.14 1.55 QIK 0.83 1.61
CDK5 2.89 5.87 KHS1 1.47 RIPK2 1.11 1.99
CDK9 1.98 LCK 1.88 RSK2 1.20
CK1d 1.39 LIMK1 1.80 SIK 1.71
CK1e 1.54 1.70 LIMK2 1.89 SRC 0.82 1.41
CK1g3 1.24 LYN 1.16 1.40 STK33 4.20
CK2a1 2.48 MAP3K2 0.84 0.85 SYK 6.25
CK2a2 1.23 2.23 MARK2 1.27 TBK1 0.33 4.58
CSK 1.12 2.29 MARK3 1.98 TESK1 1.64
DDR1 2.27 MLK3 1.75 TGFbR1 3.06
DDR2 0.79 MSK2 1.22 TNK1 2.31
DNAPK 1.66 MST1 19.82 TYK2 2.24
EphA2 0.55 2.13 MST2 4.17 Wee1 3.82
EphB1 0.80 MYT1 3.34 YES 0.54 1.63
FC (GA+MG132 vs GA) FC (GA+MG132 vs GA) FC (GA+MG132 vs GA)
significant increase by MG132 addition
no significant increase by MG132 additon
Figure 3 Proteasome inhibition effects on kinase levels in geldanamycin-treated cells. Relative quantification of kinases identified from
Hs68 and SW480 cells treated with geldanamycin for 24 h with or without MG132 addition following enrichment on Kinobeads (from two
independent experiments). Fold change refers to the ratio between geldanamycin + MG132-treated and geldanamycin-treated cells. Kinases are
highly significantly increased (dark orange or blue) when fold change is > 1.2 and p-value < 0.01. FC - fold change.
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Page 7 of 12JAK1), while the response in the second one is unal-
tered. These mutations are likely independent of Hsp90
or at least depend on additional factors that are outside
the scope of this work (Figure 4a). In many other cases,
the presence of a mutation shows limited impact on
kinase levels (e.g. TAO1, EphA4, FYN, ARG). These
mutations do not affect the stability of the kinases in
such a way that it modifies their dependency on Hsp90
chaperone machinery.
We wanted to investigate the possible molecular basis
o ft h ee f f e c t sw eo b s e r v e d .T h e r e f o r ew eu s e de x i s t i n g
structural information for t h ek i n a s ew h i c hw a sm o s t
strongly affected by a mutation, receptor-interacting ser-
ine-threonine kinase 2 (RIPK2). We mapped the affected
residues and tried to predict the functional impact of
the mutation located within the kinase domain. A
charge-rich loop of the kinase domain has been pro-
posed as the binding region of Hsp90 on some clients
like ERBB1/EGFR [27]. We found structural conserva-
tion between ERBB1 and RIPK2, which enabled us to
map this loop onto the structures of our candidate pro-
tein (Figure 4b). The residue R123 in RIPK2 is adjacent
to the charge-rich loop and directly interacts with Tyr77
within this region (Figure 4c left and middle). In the
Hsp90-
binding
loop
Arg 123 Arg 123
Hsp90 binding 
loop
wt R123
Tyr 77
His 123
Hsp90 binding 
loop
R123H
Tyr 77
B
í10
í0
0
0
10
log2 ratio
difference
A
H
s
6
8
S
W
4
8
0
U
2
O
S
A

4
9
CaMK1d * *
CDK2 * *
TAO1 * * *
ARG **
ZAK *
BRD3 *
CaMK2g *
DDR1 *
EphA2 *
EphA4 **
EphB2 *
FYN *
ILK *
JAK1 **
MAP3K1 *
MAP3K4 *
GCK **
MARK2 **
MET *
PAK4 * PDGFRb *
RIPK2 *
TAO3 *
TESK2 *
* missense mutation detected
C
Figure 4 Analysis of the effect of mutations on the response to Hsp90 inhibition. a) Kinases with a mutation detected by next generation
sequencing. Shown are the differences in the response to geldanamycin. For each kinase the non-mutated cell line most weakly responding
was used as a reference for comparison with the response in the other cell lines. Kinase names printed in bold are known or newly identified
candidate clients of Hsp90. b) Superposition of the kinase domains of ErbB1/EGFR (yellow), and RIPK2 (blue) shows structural conservation. c)
Potential mechanism for the differential response of RIPK2 to geldanamycin. Overview of kinase domain (left), close-up of affected region in wild
type (middle) and mutant (right) protein. In wild type RIPK2 R123 (red) interacts with Tyr77 of the putative Hsp90 recognition loop (green) (left,
middle panel). In the R123H mutant this interaction is lost (right panel).
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Page 8 of 12R123H mutant this interaction is lost, which likely
affects the geometry of the Hsp90 recognition loop (Fig-
ure 4c right). This in turn could require a stronger asso-
ciation with Hsp90 in order to maintain the tertiary
structure. This idea is supported by the finding that
RIPK2 is an Hsp90 client only in SW480 cells, but not
in Hs68 cells (Figure 3). We analysed the mutational
pattern of all kinases quantified in our Kinobead assay
and could correlate a subset of these mutations with a
differential response of the kinases to Hsp90 inhibition.
In the case of RIPK2 we propose that the mutation
affects kinase stability by changing the geometry of the
putative Hsp90 recognition site in this protein.
Discussion
In the past, several studies have analysed the cellular
response to multiple Hsp90 inhibitors in different cell
lines and organisms. Genome-wide expression profiling
has been employed to monitor the cellular response to
Hsp90 inhibition and revealed affected genes and mar-
kers for monitoring of effective Hsp90 inhibition in clin-
ical treatment like Hsp70 [28]. However, these
transcriptional events are indirect as Hsp90 regulates
mostly the protein stability of its clients. Some studies
have however used proteomics to monitor protein levels
and revealed affected pathways like for example chroma-
tin remodelling or MAPK, WNT, NF-kB and TGF-beta
signalling [25,29]. However kinases, the largest group of
clients, were underrepresented in these studies. To close
this gap we focused on the analysis of the response to
Hsp90 inhibition of a large number of kinases by mea-
suring their protein level changes. We compared the
rate of down- or upregulation of our kinase-focussed
assay with the two abovementioned previous studies
that probed the unfiltered proteome. Schumacher et al.
identified 111 differentially expressed proteins of which
about 41% were overexpressed and 59% underexpressed
[25]. Similar values were found by Maloney et al.( 2 6
proteins in total, 46% over- and 54% underexpressed)
[29]. Comparing these values to significant downregula-
tion of 69% to 88% of all identified kinases by our assay
argues for a high specificity of kinase level reduction
after Hsp90 inhibition.
A higher affinity to Hsp90 inhibitors has been
reported in cancer cells [7]. We investigated if there
were different kinetics of client degradation between
normal and cancer cells in response to geldanamycin.
Interestingly, we did not find striking differences arguing
that kinetic properties do not contribute to the
increased response to Hsp90 inhibition in cancer cells.
We only observed slower kinetics in U2OS cells, which
may be due to reduced transport of the drug into the
cell or differences in metabolism of the drug. For exam-
ple, it has been shown for 17-allylamino,17-
demethoxygeldanamycin (17-AAG), a geldanamycin
derivative, that activity of the quinone reductase DT-dia-
phorase (gene name: NQO1) is positively correlated with
the growth-inhibitory activity of 17-AAG, because DT-
diaphorase converts 17-AAG into a form more potent
for Hsp90 inhibition [30].
Our kinase-enrichment approach allowed us to moni-
tor the effect of the Hsp90 inhibitor geldanamycin on
144 kinases. From this data we were able to identify 44
high confidence client kinase candidates (Figure 1b)
with a strong representation of MAPK and TGF-beta
signalling components (Figure 2c). The additional treat-
ment with proteasome inhibitor MG132 allowed us to
discriminate between Hsp90 client candidates that likely
undergo ubiquitination and proteasomal degradation
(their cellular levels are at least partially recovered in
presence of MG132) and kinases that are affected by
geldanamycin treatment more indirectly - for example
via transcriptional regulation if downstream of a client
kinase - or via another mechanism (their cellular levels
should not be significantly changed in presence of
MG132). Whereas a majority of kinases affected by gel-
danamycin treatment appears to be true client Hsp90
proteins in SW480, only few kinases displays a similar
behaviour in Hs68. Based on these results, we propose a
list of Hsp90 client kinases (Figure 3). This list regroups
64 kinases and includes many tyrosine kinases (e.g. Fyn,
Lyn, Src, Yes, Abl, Arg, Tyk2) or tyrosine-like kinases
(ALK2, ALK4, RIPK2, ILK, TGFBR1, MLK3), two phylo-
genic branches of kinases that have previously been
shown to include most of the Hsp90 kinase clients [27].
Ephrin receptors distinguish themselves among tyrosine
kinases since - with the noticeable exception of Epha2
-, they do not appear to be Hsp90 clients, at least in
SW480 cells. Among the Serine/Threonine kinase
groups, we find well-described Hsp90 clients like CDK2,
CDK9, CK2a1, CK2a2 or TBK1 but also some kinases
that were thought not to be Hsp90 clients based on
their sequence [27] like CDK5, PKCa,P K C b or
MAPK1/ERK2. Conversely, among kinases that did not
appear as Hsp90 clients in this study, we find some
kinases that have been previously described as putative
Hsp90 clients like GSK3b,J A K 1o rF E R .O u rl i s to f
Hsp90 client kinases is therefore significantly different
from those that have been proposed so far [27,31]. Gel-
danamycin treatment affects many pathways and has
major impact on the entire proteome [25]. It is therefore
not too surprising that the level of many kinases is sig-
nificantly modified even if their levels are poorly regu-
lated by Hsp90 machinery, like many kinases from Hs68
cells. This data strongly support the hypothesis that the
role of Hsp90 as a kinase chaperone is much less pre-
eminent in healthy primary cells than in a cancer cell
type as colon adenocarcinoma SW480 cells. We
Haupt et al. BMC Cancer 2012, 12:38
http://www.biomedcentral.com/1471-2407/12/38
Page 9 of 12conclude from our results that in normal cells the
majority of downregulated kinases following geldanamy-
cin treatment is driven by indirect, non Hsp90-depen-
dent mechanisms of degradation. In contrast, in cancer
cells the majority of kinases appear to be dependent on
Hsp90 chaperoning.
Many Hsp90 inhibitors have been developed and sev-
eral are presently undergoing clinical evaluation [5].
This is the first study that focuses on the impact of
Hsp90 inhibition on a broad spectrum of the kinome.
Our results reveal an impact of Hsp90 inhibitors on
more wide-ranging types of kinases, and hence path-
ways, than previously thought (Figure 1b and 2c). This
is of special clinical interest for the inhibition of feed-
back loops that often arise in single targeted therapy
and that have been acknowledged as a resistance
mechanism and escape route for cancers to evade treat-
ment. For example the use of mTOR inhibitors leads to
the PI3K-dependent activation of MAPK and Akt signal-
ling, which both are targeted by Hsp90 inhibitors
[32,33]. Our discovery of many new Hsp90 targets
further supports the use of Hsp90 inhibitors in combi-
natorial treatment, especially as a means to suppress
feedback loops, because it affects even more processes
than anticipated so far.
Many kinases annotated by KEGG as members of
TGF-beta signalling identified in our study belong to
the bone morphogenetic protein (BMP) signalling path-
way. We show for the first time that BMP receptors
(BMPR1A, BMPR2, ACTR2, ALK2 and ALK4) exhibit
downregulation after Hsp90 inhibition (Figure 1). BMP
proteins are members of the TGF-beta superfamily and
have important functions including embryonic develop-
ment, bone formation and tissue homeostasis [34].
BMPs bind to BMP receptors that mediate signals
mostly via phosphorylation of SMADs [34]. In cancer,
this pathway has been linked for example to bone
metastases formation in breast, prostate and lung cancer
and control of cell proliferation. The outcome of BMP
receptor signalling is strongly cell type- specific and also
dependent on which BMPs are present [35]. Therefore
the consequences of downregulation of multiple BMP
receptors by Hsp90 inhibition could be diverse in differ-
ent tissues. In prostate cancer BMPR1A and especially
BMPR2 downregulation has been correlated with disease
progression and activity of BMPR2 has been shown to
function in a proliferation suppressive way [36,37]. Our
findings suggest that the use of Hsp90 inhibitors in
prostate cancer might, by the downregulation of
BMPRs, lead to an unintended promotion of prolifera-
tion and metastasis formation, thereby counteracting or
attenuating the beneficial effects exerted on other path-
ways and limiting its clinical use. In line with this,
results from a clinical trial with hormone-refractory
prostate cancer suggest that Hsp90 inhibitors are no
effective agents when used in monotherapy [38]. If this
is attributable to their effects on BMPRs remains to be
determined. In contrast, in breast cancer BMPR1A activ-
ity was shown to promote cell proliferation via SMADs,
whereas results for BMPR2 are contradictory [39-41].
This indicates that there might be a more promising
therapeutic window for the use of Hsp90 inhibitors to
reduce BMP signalling in certain breast cancers, in
which setting several Hsp90 inhibitors are currently
tested [5].
Our study identified many kinases of the JNK and p38
MAPK pathways, which are involved in diverse pro-
cesses like for example stress response, inflammation,
cell proliferation, survival and migration. Both pathways
are often deregulated in cancer, however the often con-
text-specific oncogenic and tumour suppressive func-
tions impede the prediction of a pharmacological
intervention [40]. We identified new Hsp90 targets
within the p38, JNK and also Erk5 MAPK signalling cas-
cades on the level of MAPKKKs (MEKK2/3/4, MLK1/3,
TAO1/2 and ZAK) and upstream regulatory MAP4Ks
( G C K ,K H S 1 ,K H S 2 )a n dc o u l ds h o wa ni n c r e a s e d
downregulation in cancer cells upon geldanamycin treat-
m e n tf o rs o m eo ft h e m( F i g u r e1a n d2 b ) .S e v e r a li n h i -
bitors of p38alpha and JNK have been developed, but
have side effects or lacked specificity [42]. We do not
propose Hsp90 inhibitors as a single agent treatment in
this setting, however it might prove useful for combina-
torial treatment with future improved inhibitors against
JNK and p38, because they can downregulate several
upstream components of the MAPK cascades, likely
increasing the efficacy of inhibition. As Hsp90 inhibitors
act more specifically on tumours this additional effect
would be limited to the target tissue, which likely mini-
mises systemic side effects.
Conclusions
Our findings emphasise the influence of the underlying
genetic background of individual tumours on the
response to Hsp90 inhibitors. In addition we find a large
range of kinases more strongly destabilized and more
dependent on Hsp90 chaperoning in the examined can-
cer cell lines when compared to a primary, phenotypi-
cally normal cell line. In the future the establishment of
chemoproteomic and mutational profiles, that analyse
responsiveness to Hsp90 inhibition in different cancer
types, will help to identify patients that can benefit from
this treatment especially by combinatorial treatment.
Recently, efforts to establish mutational profiles of lung
cancer have been undertaken and showed promising
results for mutation-specific treatment, for example of
tumour cells showing ras mutations, with an Hsp90
inhibitor [43].
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